Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Hypersensitivity to Febuxostat in a Patient with a Previous Allopurinolinduced Steven-Johnson Syndrome: A Case Report of Treatment with a Slow Desensitization Protocol

Author(s): Gianfranco Calogiuri*, Maurizio Congedo, Eustachio Nettism, Luigi Macchia, Caterina Foti and Angelo Vacca

Volume 22, Issue 8, 2022

Published on: 25 May, 2022

Page: [895 - 899] Pages: 5

DOI: 10.2174/1871530322666220404200918

Price: $65

Abstract

Background: We report the case of a 43-year-old Chinese male with Tophaceous gout who had been living in Italy for some years.

Case Presentation: Previous treatments with allopurinol had induced Steven Johnson syndrome, dictating a switch to febuxostat 80 mg daily. After two years of treatment with febuxostat, he developed a diffuse maculopapular rash with severe itching. Rheumatologists stopped febuxostat; however, gout worsened over the following years despite treatment with kalnicitrate and colchicine. Therefore, an allergy consultation was called for. A slow desensitization protocol with febuxostat was started, with a low oral dosage scheme to be increased up to 80 mg/day. Febuxostat was prepared in a solid formulation by the consultation pharmacist as pills instead of the more frequently used liquid suspension.

Conclusion: The patient is currently receiving febuxostat 80 mg, and he has shown no side effects as of now, while his gout has improved. This is the first reported example and he has shown no side effect till now, while his gout improved of a successful desensitization protocol using a solid preparation of diluted febuxostat given as pills.

Keywords: Allopurinol, drug desensitization, febuxostat, hypersensitivity, skin rash, Steven-Johnson syndrome.

« Previous
Graphical Abstract

[1]
Yu, K.H. Febuxostat: A novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat. Inflamm. Allergy Drug Discov., 2007, 1(1), 69-75.
[http://dx.doi.org/10.2174/187221307779815020] [PMID: 19075968]
[2]
Becker, M.A.; Schumacher, H.R., Jr; Wortmann, R.L.; MacDonald, P.A.; Eustace, D.; Palo, W.A.; Streit, J.; Joseph-Ridge, N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med., 2005, 353(23), 2450-2461.
[http://dx.doi.org/10.1056/NEJMoa050373] [PMID: 16339094]
[3]
Calogiuri, G.; Nettis, E.; Di Leo, E.; Foti, C.; Ferrannini, A.; Butani, L. Allopurinol hypersensitivity reactions: Desensitization strategies and new therapeutic alternative molecules. Inflamm. Allergy Drug Targets, 2013, 12(1), 19-28.
[http://dx.doi.org/10.2174/1871528111312010004] [PMID: 23092365]
[4]
Abeles, A.M. Febuxostat hypersensitivity. J. Rheumatol., 2012, 39(3), 659.
[http://dx.doi.org/10.3899/jrheum.111161] [PMID: 22383358]
[5]
Chou, H.Y.; Chen, C.B.; Cheng, C.Y.; Chen, Y.A.; Ng, C.Y.; Kuo, K.L.; Chen, W.L.; Chen, C.H. Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). J. Clin. Pharm. Ther., 2015, 40(6), 689-692.
[http://dx.doi.org/10.1111/jcpt.12322] [PMID: 26365588]
[6]
Paschou, E.; Gavriilaki, E.; Papaioannou, G.; Tsompanakou, A.; Kalaitzoglou, A.; Sabanis, N. Febuxostat hypersensitivity: Another cause of DRESS syndrome in chronic kidney disease? Eur. Ann. Allergy Clin. Immunol., 2016, 48(6), 251-255.
[PMID: 27852432]
[7]
Yin, Y.F.; Guo, Y.; Song, W.D.; Duan, X.C.; Zheng, X.C.; Zhong, T.; Zhang, S.; Yao, X.; Xu, M.Q.; Zhang, Q.; Zhang, X. Improving solubility and oral bioavailability of febuxostat by polymer-coated nanomatrix. AAPS PharmSciTech, 2018, 19(2), 934-940.
[http://dx.doi.org/10.1208/s12249-017-0905-z] [PMID: 29079988]
[8]
Cernadas, J.R.; Brockow, K.; Romano, A.; Aberer, W.; Torres, M.J.; Bircher, A.; Campi, P.; Sanz, M.L.; Castells, M.; Demoly, P.; Pichler, W.J. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy, 2010, 65(11), 1357-1366.
[http://dx.doi.org/10.1111/j.1398-9995.2010.02441.x] [PMID: 20716314]
[9]
Scherer, K.; Brockow, K.; Aberer, W.; Gooi, J.H.; Demoly, P.; Romano, A.; Schnyder, B.; Whitaker, P.; Cernadas, J.S.; Bircher, A.J. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy, 2013, 68(7), 844-852.
[http://dx.doi.org/10.1111/all.12161] [PMID: 23745779]
[10]
Vázquez-Mellado, J.; Vázquez, S.G.; Barrientos, J.C.; Ríos, V.G.; Burgos-Vargas, R. Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout. J. Clin. Rheumatol., 2000, 6(5), 266-268.
[http://dx.doi.org/10.1097/00124743-200010000-00006] [PMID: 19078483]
[11]
Sullivan, T. Protocols for rapid and slow drug allergy desensitization, First Edition; Atlanta, 2009, p. 32.
[12]
Sulaiman, N.; Othman, A.Z.S.; Shahril, N.S.; Abdul Rashid, A.M.; Md Noh, M.S.F. Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience. SAGE Open Med. Case Rep., 2017, 5, X17749080.
[http://dx.doi.org/10.1177/2050313X17749080] [PMID: 29318019]
[13]
Tana, T.; Vadas, P. Febuxostat desensitization in a patient with previous Steven Johnson syndrome and HLA-B58:01 genotype. J. Rheumatol., 2019, 46(9), 1250-1251.
[http://dx.doi.org/10.3899/jrheum.181051] [PMID: 31308200]
[14]
Asgarpour, J.; Vadas, P. Successful desensitization to febuxostat in a patient with recalcitrant gout and a history of hypersensitivity reactions to both febuxistat and allopurinol. Abstract book of the 24th World Congress Dermatology; Milan [Italy], 2019.
[15]
Di Paolo, C.; Minetti, S.; Mineni, M.; Inverardi, S.; Rizzini, F.L.; Cinquini, M.; Tosoni, C. Desensitization to febuxostat: Report of two cases. J. Allergy Clin. Immunol. Pract., 2015, 3(4), 633-636.
[http://dx.doi.org/10.1016/j.jaip.2015.01.022] [PMID: 25758914]
[16]
Koenig, D.; Royer, C.; Azar, A. Successful desensitization to febuxostat in a patient with hypersensitivity to allopurinol and febuxostat and review of the literature. J. Clin. Rheumatol., 2021, 27(8S), S432-S433.
[http://dx.doi.org/10.1097/RHU.0000000000001296] [PMID: 31977653]
[17]
Jarjour, S.; Barrette, M.; Normand, V.; Rouleau, J.L.; Dubé, M.P.; de Denus, S. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: A systematic review. Pharmacogenomics, 2015, 16(7), 755-767.
[http://dx.doi.org/10.2217/pgs.15.21] [PMID: 25965122]
[18]
Bardin, T.; Chalès, G.; Pascart, T.; Flipo, R.M.; Korng Ea, H.; Roujeau, J.C.; Delayen, A.; Clerson, P. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine, 2016, 83(3), 314-317.
[http://dx.doi.org/10.1016/j.jbspin.2015.07.011] [PMID: 26709250]
[19]
Singh, J.A.; Cleveland, J.D. Hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data. Ann. Rheum. Dis., 2020, 79(4), 529-535.
[http://dx.doi.org/10.1136/annrheumdis-2019-216917] [PMID: 32024648]
[20]
Quilis, N.; Vela, P.; Blanco Cáceres, B.A.; Diaz-Torne, C.; Calvo-Aranda, E.; Sivera, F. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: Comment on the article by Singh and Cleveland. Ann. Rheum. Dis., 2020, 218226.
[http://dx.doi.org/10.1136/annrheumdis-2020-218226]
[21]
Lien, Y.H.H.; Logan, J.L. Cross-reactions between allopurinol and febuxostat. Am. J. Med., 2017, 130(2), e67-e68.
[http://dx.doi.org/10.1016/j.amjmed.2016.08.042] [PMID: 27667702]
[22]
Yun, J.; Marcaida, M.J.; Eriksson, K.K.; Jamin, H.; Fontana, S.; Pichler, W.J.; Yerly, D. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B.58:01. J. Immunol., 2014, 192(7), 2984-2993.
[http://dx.doi.org/10.4049/jimmunol.1302306] [PMID: 24591375]
[23]
Kuriyama, S. Dotinurad: A novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. Clin. Exp. Nephrol., 2020, 24(Suppl. 1), S1-S5.
[http://dx.doi.org/10.1007/s10157-019-01811-9]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy